(Q34754599)

4 August 2017

title

Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study (English)

1 reference

neuroleptic malignant syndrome

4 August 2017

1 reference

1 reference

3

Keck PE Jr

1 reference

4 August 2017

Berardi D

1

1 reference

4 August 2017

Amore M

series ordinal

2

1 reference

4 August 2017

Troia M

series ordinal

4

1 reference

4 August 2017

Dell'Atti M

series ordinal

5

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 October 1998

1 reference

4 August 2017

published in

Biological Psychiatry

1 reference

4 August 2017

volume

44

1 reference

4 August 2017

issue

8

1 reference

4 August 2017

page(s)

748-754

1 reference

Neuroleptic malignant syndrome: review and analysis of 115 cases

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Spectrum concept of neuroleptic malignant syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Akathisia variants and tardive dyskinesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Neuroleptic malignant syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Dose equivalence of the antipsychotic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Neuroleptic catatonia and its relationship to psychogenic catatonia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

7 January 2021

The catatonic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Catatonic reactions to high-potency neuroleptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Pridinolum mesylate and neuroleptic malignant syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Lethal catatonia complicated by the development of neuroleptic malignant syndrome in a middle-aged female.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Lethal catatonia and neuroleptic malignant syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

The neuroleptic malignant syndrome: review and report of three cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Risk for definite neuroleptic malignant syndrome. A prospective study in 223 consecutive in-patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Risk factors for neuroleptic malignant syndrome. A case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Neuroleptic malignant syndrome and malignant hyperthermia: end of a controversy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Neuroleptic-induced catatonia or a mild form of neuroleptic malignant syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Neuroleptic malignant syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Rigidity, hyperpyrexia and coma following fluphenazine enanthate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Risperidone-induced neuroleptic malignant syndrome: a case report and review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Neuroleptic malignant syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Incidence and risk factors in neuroleptic malignant syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Lethal catatonia and neuroleptic malignant syndrome. A dopamine receptor shut-down hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Neuroleptic therapy following neuroleptic malignant syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Neuroleptic malignant syndrome in multiple sclerosis. Possible masking effects of antispasmodics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

A prospective analysis of 24 episodes of neuroleptic malignant syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

The neuroleptic malignant syndrome: agent and host interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

The role of loading rate in neuroleptic malignant syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

The role of external heat load in triggering the neuroleptic malignant syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Reinstitution of neuroleptic treatment with molindone in a patient with a history of neuroleptic malignant syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

A possible variant of the neuroleptic malignant syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

The neuroleptic malignant syndrome manifested as a prolonged confusional state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Incipient neuroleptic malignant syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

Catatonia and the neuroleptic malignant syndrome--a single entity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900530-1

10.1016/S0006-3223(97)00530-1

7 January 2021

Identifiers

DOI

1 reference

4 August 2017

1 reference